Flubio is developed by Indonesia University.

What development phase is Flubio in?

Flubio is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Flubio

Indonesia University · FDA-approved active Biologic Quality 0/100

At a glance

Generic name	Flubio
Sponsor	Indonesia University
Modality	Biologic
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Probiotic and Influenza Vaccination to Reducing Influenza-like Illness Incident in Elderly (PHASE4)
Immunogenocity and Safety of Flubio (Influenza HA) Vaccine in Infants and Children (Bridging Study) (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Flubio CI brief — competitive landscape report
Flubio updates RSS · CI watch RSS
Indonesia University portfolio CI